Gene therapy company
Appears in 1 story · Last updated Nov 11, 2026
Markets Lyfgenia; formerly Bluebird Bio
Beam Therapeutics said Tuesday that its sickle cell treatment, risto-cel, met the main goal of a late-stage trial: patients stayed free of severe pain crises for at least 12 months. It is the first positive late-stage result for base editing, a gene-editing method that changes individual DNA letters without cutting the strand. Beam plans to file for FDA approval as early as the end of 2026.
Updated 3 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
